Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

48.200
-1.460-2.94%
Volume:10.03M
Turnover:484.39M
Market Cap:319.90B
PE:35.01
High:49.660
Open:49.660
Low:47.600
Close:49.660
52wk High:94.869
52wk Low:47.600
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.00
T/O Rate:3.89%
Dividend:0.23
Dividend Rate:0.48%
EPS(LYR):1.377
ROE:12.46%
ROA:7.02%
PB:4.25
PE(LYR):35.01
PS:8.75

Loading ...

Hengrui Pharma's Self-Developed Class 1 Biologic Insulin Analogue Receives Market Approval

Stock News
·
Jul 29

Jiangsu Hengrui Receives Approval for China's First Self-Developed Long-Acting Insulin Analog

Stock News
·
Jul 29

Market Highlights: First Domestically Developed Long-Acting Diabetes Treatment Approved, Hengrui Pharma Leads

Stock News
·
Jul 29

Hengrui Pharma's Recombinant Anti-Tumor Antibody Injection Receives NMPA Approval Application Submission

Stock News
·
Jul 29

AH Premium Data Overview: July 29 Market Close

Stock News
·
Jul 29

AH Share Premium and Discount Report for July 28

Stock News
·
Jul 28

Jiangsu Hengrui Pharmaceuticals Gets China Nod for Hypertension Drug Trial

MT Newswires Live
·
Jul 28

Hengrui Pharmaceuticals' Pancreatic Cancer Drug Gets US FDA Orphan Status

MT Newswires Live
·
Jul 28

Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy

MT Newswires Live
·
Jul 27

Citigroup’s Short Position in H-shares of Jiangsu Hengrui Pharmaceuticals Decreases to 2.53% on July 20 from 3.07% - HKEX Filing

THOMSON REUTERS
·
Jul 24

Cross-Listed Stock Premium Report: Closing Data for July 24

Stock News
·
Jul 24

Hengrui Pharma gains NMPA approval for camrelizumab-famitinib as first-line treatment in recurrent/metastatic cervical cancer

Bulletin Express
·
Jul 23

AH Share Premium and Deviation Data for July 22nd

Stock News
·
Jul 22

Movement Alert|Hengrui Pharma Falls 3.22% in Regular Trading, Trading at HK$55.6

Market Focus
·
Jul 21

AH Share Premium and Deviation Data for July 20th

Stock News
·
Jul 20

Movement Alert|Hengrui Pharma Rises 3.36% in Regular Trading, Pharmaceutical Sector Rebounds as Buyback Program Advances

Market Focus
·
Jul 20

Hengrui Pharmaceuticals Completes Share Buyback Totaling 13.75 Million A-Shares

Stock News
·
Jul 19

Hengrui Pharma Executes Share Buyback, Spending Over 15 Million Yuan on July 17

Stock News
·
Jul 17

Hengrui Pharma Gets China Clinical Trial Nod for Osteoarthritis Injection; Shares Fall 4%

MT Newswires Live
·
Jul 17

Movement Alert|Hengrui Medicine Falls 3.19% in Regular Trading, Pharmaceutical Sector Broadly Weak Despite Pipeline Progress

Market Focus
·
Jul 17